‘Trelegy 200 Ellipta Inhaler,’ a triple combination therapy for COPD, has completed the negotiations with the National Health Insurance Service (NHIS). The drug is expected to be listed for health insurance reimbursement soon.

According to industry experts on the 13th, ‘Trelegy 200 Ellipta Inhaler,’ a COPD triple combination therapy, has completed the negotiations with the NHIS and is expected to be listed for reimbursement after the final reporting to the Health Insurance Policy Review Committee.

This drug has a unique feature of doubling the dosage of GSKs first triple combination therapy Trelegy Ellipta (ICS/LABA/LAMA). ‘Trelegy 200 Ellipta’ is used as a maintenance the